Skip to main content

Table 7 Univariate analysis of clinicopathological factors for OS and DFS in patients received NAC (n = 78)

From: CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer

Variables

OS

DFS

HR(95% CI)

P value

HR(95% CI)

P value

Age

0.7963(0.3753–1.689)

0.5528

0.6167(0.3178–1.197)

0.1531

Gender

0.5719(0.2129–1.536)

0.2678

0.3019(0.1163–0.7836)

0.0138

Smoking history

1.648(0.7097–3.827)

0.2452

2.134(0.976–4.663)

0.0575

Histology

0.4711(0.2217–1.001)

0.0503

0.351(0.1761–0.6996)

0.0029

Histologic grading

1.425(0.6849–2.964)

0.3435

1.714(0.8874–3.312)

0.1086

Venous invasion

0.6148(0.2552–1.482)

0.2784

0.7369(0.3251–1.670)

0.4645

Pathological stage

0.3958(0.1894–0.8274)

0.0137

0.3351(0.1717–0.6540)

0.0014

CMTM1_v17 expression

0.3095(0.1442–0.6643)

0.0026

0.3655(0.1871–0.7142)

0.0032

  1. P value was calculated using a two-sided log-rank test
  2. NAC neoadjuvant chemotherapy, HR hazard ratio (log-rank), CI confidence interval.
  3. Bold values are significant (P < 0.05)
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us